An intravenous application of magnetic nanoparticles for osteomyelitis treatment: An efficient alternative

Basit Öğe Kaydı
dc.authoridUyanikgil, Yigit/0000-0002-4016-0522
dc.authoridUyanikgil, Yigit/0000-0002-4016-0522
dc.authoridUyanikgil, Yigit/0000-0002-4016-0522
dc.authoridak, Güliz/0000-0001-9613-6348
dc.authoridYİLMAZ, HABİBE/0000-0003-1106-0458
dc.authoridTomruk, Canberk/0000-0002-3810-3705
dc.authoridSANLIER, SENAY/0000-0001-6532-7221
dc.authorwosidUyanikgil, Yigit/M-2746-2019
dc.authorwosidUyanikgil, Yigit/KLY-8722-2024
dc.authorwosidUyanikgil, Yigit/KIE-9628-2024
dc.authorwosidak, Güliz/M-2796-2018
dc.authorwosidYİLMAZ, HABİBE/AAG-5274-2019
dc.authorwosidTomruk, Canberk/AAN-4976-2020
dc.authorwosidSANLIER, SENAY/AAG-3087-2021
dc.contributor.authorAk, Guliz
dc.contributor.authorBozkaya, Ummuhan Fulden
dc.contributor.authorYilmaz, Habibe
dc.contributor.authorTurgut, Ozge Sari
dc.contributor.authorBilgin, Ismail
dc.contributor.authorTomruk, Canberk
dc.contributor.authorUyanikgil, Yigit
dc.date.accessioned2024-06-12T11:11:46Z
dc.date.available2024-06-12T11:11:46Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe infection of bone and bone marrow is called osteomyelitis. Treatment is difficult since antibiotics can not reach with enough concentration to the infected area. For the first time in this study, we have developed gentamicin-loaded magnetic gelatin nanoparticles (GMGNPs) for nanocarrier-mediated and magnetically targeted osteomyelitis therapy. Gelatin, genipin, and magnetite were used for preparation of that novel carrier system due to their biodegradable and biocompatible properties. Cross-linking degree of gelatin nanoparticles, concentration of magnetite nanoparticles, and adsorbed drug amount were optimized. Furthermore, nanoparticles were characterized and the drug release profile was determined. The osteomyelitis model was constituted in the proximal tibia of rats. The therapeutic potential of GMGNPs on rats was monitored via X-Ray radiography and hematological and histopathological analyses were performed. According to the results, 110.3 +/- 8.2 mu g gentamicin/mg GMGNPs were used, hydrodynamic size was measured as 253.7 +/- 11.8 nm, and GMGNPs have controlled drug release profile. Based on in vivo and ex vivo studies, after six doses of GMGNPs treatment, abscess began to heal and the integrity of periost and bone began to reconstruct. In conclusion, it can be suggested that GMGNPs could provide efficient therapy for osteomyelitis.en_US
dc.description.sponsorshipEge University Scientific Research Project Office [2014 ILAM 001]; Ege University [78886088 - 604.01.06]en_US
dc.description.sponsorshipThis study was financially supported by Ege University Scientific Research Project Office (Grand number: 2014 ILAM 001). We would like to thank Ege University Center for Drug Research & Development and Pharmacokinetic Applications (ARGEFAR) for the laboratory support, Dr. E. Gulben Yurdagul for her interpretation of X-Ray images, Dursun Demiroz for providing illustrations and technical support, and also Erkan Aydin for checking and correcting the language of our article. Patent applications in the national and international areas have been filed for this invention, which have been supported by Ege University (paperwork issue number 78886088 - 604.01.06).en_US
dc.identifier.doi10.1016/j.ijpharm.2020.119999
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.pmid33190790en_US
dc.identifier.scopus2-s2.0-85095840846en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2020.119999
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22919
dc.identifier.volume592en_US
dc.identifier.wosWOS:000600740100006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal Of Pharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOsteomyelitisen_US
dc.subjectGelatin Nanoparticleen_US
dc.subjectMagnetiteen_US
dc.subjectGentamicinen_US
dc.subjectGenipinen_US
dc.subjectMagnetic Drug Targetingen_US
dc.subjectImplant-Related Osteomyelitisen_US
dc.subjectIron-Oxide Nanoparticlesen_US
dc.subjectGelatin Nanoparticlesen_US
dc.subjectStaphylococcus-Aureusen_US
dc.subjectDelivery-Systemen_US
dc.subjectDrug-Deliveryen_US
dc.subjectGentamicinen_US
dc.subjectReleaseen_US
dc.subjectInjectionen_US
dc.subjectGenipinen_US
dc.titleAn intravenous application of magnetic nanoparticles for osteomyelitis treatment: An efficient alternativeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu